Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC S23 healthcare AI phone agents automating 50-70% of inbound calls for scheduling, prior auth, and claims; $5M Emergence Capital seed Sep 2025 with 4x revenue growth competing with Nuance and Luma Health for the $200B healthcare admin voice automation market.
Prosper AI is a San Francisco-based healthcare AI voice automation company — backed by Y Combinator (S23) with $5 million in seed funding in September 2025 led by Emergence Capital — providing healthcare providers with AI phone agents that automate inbound patient call workflows including patient scheduling, balance reminders, claims status checks, benefits verification, and prior authorization status inquiries — achieving 50-70% inbound call automation rates with 99% IVR navigation accuracy. Founded in 2023 by Josep Mingot and Xavier de Gracia (MIT and Harvard alumni), Prosper AI achieved 4x revenue growth since Q2 2025, addressing the $450 billion US healthcare administrative overhead crisis where an estimated $200 billion in administrative costs come from phone-based patient-provider communication inefficiencies.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.